Breath Therapeutics, a Zambon company, initiates BOSTON-3 and BOSTON-4, two additional clinical studies for the treatment of bronchiolitis obliterans syndrome (BOS)

Breath Therapeutics, a Zambon company, initiates BOSTON-3 and BOSTON-4, two additional clinical studies for the treatment of bronchiolitis obliterans syndrome (BOS)

Published

News published by Breath Therapeutics concerning L-CsA-i, administered via an optimized investigational eFlow® Technology nebulizer.
 

Read the press release

Back to overview